Filtered By:
Education: Study
Therapy: Incretin Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 62 results found since Jan 2013.
Role of GLP-1 receptor agonist in diabetic cardio-renal disorder: Recent updates of clinical and pre-clinical evidence
Curr Diabetes Rev. 2023 Aug 9. doi: 10.2174/1573399820666230809152148. Online ahead of print.ABSTRACTCardiovascular complications and renal disease is the growing cause of mortality in patients with diabetes. The subversive complications of diabetes such as hyperglycemia, hyperlipidemia and insulin resistance lead to an increase in the risk of myocardial infarction (MI), stroke, heart failure (HF) as well as chronic kidney disease (CKD). Among the commercially available anti-hyperglycemic agents, incretin-based medications appear to be safe and effective in the treatment of type 2 diabetes mellitus (T2DM) and associated ca...
Source: Current Diabetes Reviews - August 10, 2023 Category: Endocrinology Authors: Sanket Seksaria Bhaskar Jyoti Dutta Mandeep Kaur Ghanshyam Das Gupta Surendra H Bodakhe Amrita Singh Source Type: research
Incretin-based therapy of metabolic disease
Dan Med J. 2022 Dec 21;70(1):A10220597.ABSTRACTRecent studies show that incretin hormone analogues effectively control blood glucose while producing major weight losses and reducing the risk of all-cause mortality, myocardial infarction, stroke and kidney function impairment. Furthermore, the risk of dementia and cognitive impairment is reduced. A monomolecular coagonist (tirzepatide) of receptors for both incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) produced HbA1c values below 5.7% in 50% of the treated patients and weight losses exceeding 20% in obese individuals. These new...
Source: Danish Medical Journal - January 11, 2023 Category: General Medicine Authors: Jens Juul Holst Source Type: research
